Texas Sues Pfizer Over Tainted Children’s Drugs

By Tyler Durden

Texas Attorney General Ken Paxton has sued Pfizer and Tris Pharma “for defrauding the Texas Medicaid program by providing adulterated pharmaceutical drugs to Texas children.”

Specifically, Pfizer’s ADHD drug “Quillivant XR” was “knowingly distributed” to children on Medicaid despite the drugmaker’s “pattern of failing quality control tests” due to a flawed manufacturing process by Tris, which Pfizer contracted with to produce the drug, according to the complaint.

I am horrified by the dishonesty we uncovered in this investigation,” said Texas AG Ken Paxton. “Pfizer and Tris intentionally concealed and failed to disclose the issues with Quillivant to receive taxpayer funded benefits through Texas Medicaid, defrauding the state and endangering children. Our Civil Medicaid Fraud Division has done an outstanding job holding these pharmaceutical companies accountable.”

According to the filing, “At no point did Defendants warn Texas Medicaid providers or decision-makers that Quillivant had known manufacturing issues affecting its efficacy, thereby depriving the Medicaid program of the crucial information it relies on.… As a result, thousands of Texas children received an adulterated Schedule II Controlled Dangerous Substance.”

The lawsuit, initially filed under seal, was unsealed at the AG’s request.

“I am horrified by the dishonesty we uncovered in this investigation,” said Texas AG Ken Paxton.

Download PDF

Source: ZeroHedge

Become a Natural Blaze Patron and Support Health Freedom

Become a Patron!

Get Natural Health News Delivered

Enter Email Below To Stay Informed!

Widget not in any sidebars

10 Best Books To Survive Food Shortages & Famines

Your survival library won’t be complete without these books!

Plus get top natural health news delivered daily. Stay informed about health and food freedom, holistic remedies, and preparedness.

Claim your FREE download TODAY!

Enter your email address below to get instant access!

Enter Email Below To Stay Informed!

Thank you for sharing. Follow us for the latest updates.
Send this to a friend